Search results
Results from the WOW.Com Content Network
In 2013 Cipla acquired the South African company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary. [11] [12] At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company. [11]
Cipla, India's No.3 generic drugmaker by sales, reported a better-than-expected quarterly profit on Friday, boosted by strength in its key domestic and North American businesses. The results come ...
Dig a bit deeper into the BBB's report and a picture emerges of which sorts of business are generating the most inquiries: Topping the list are roofers, with more than 3 million inquiries in 2011 ...
In 2023, the Indian government's Chief Economic Advisor, V Anantha Nageswaran questioned India's sovereign credit rating of BBB- by S&P and Baaa3 by Moodys and called for a review of the big three's rating methods. [14] In January 2024, CareEdge Ratings issued its Sovereign Ratings Framework for public consultation. [15]
HYDERABAD/BENGALURU (Reuters) -Cipla, India's third-largest generics drugmaker by sales, beat first-quarter profit estimates on Friday as it reported higher sales in its North America market ...
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
On July 29, Cipla an Indian pharmaceutical company bought three products from Teva. [78] Indian pharmaceutical company, Aurobindo, was in the race to buy some Teva assets. In October 2016, Teva has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds (5083 crore Indian rupees ...
The company's "Albuterol Sulfate HFA Inhalation Aerosol" is a generic therapeutic equivalent version of an inhaler from Merck & Co, US unit of India's Cipla recalls six batches of bronchospasm inhaler